SCA
GILD icon

Stokes Capital Advisors’s Gilead Sciences GILD Stock Holding History

Stokes Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47M Buy
35,370
+33,345
+1,647% +$4.39M 0.96% 38
2026
Q1 		$282K Buy
+2,025
New +$284K 0.06% 84

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Stokes Capital Advisors's GILD Position: Q2 2026 in Review

Stokes Capital Advisors increased its Gilead Sciences (GILD) stake by 1,647% in Q2 2026, buying an estimated $4.39M and bringing the position to 35,370 shares worth $4.47M. The position accounts for 0.96% of the portfolio, ranked #38.

Stokes Capital Advisors first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. 690 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Stokes Capital Advisors held 35,370 shares of Gilead Sciences worth $4.47M as of Q2 2026.
  • Stokes Capital Advisors bought 33,345 Gilead Sciences shares in Q2 2026, an estimated $4.39M.
  • Gilead Sciences made up 0.96% of Stokes Capital Advisors's portfolio in Q2 2026, its #38 holding.
  • Stokes Capital Advisors first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • 690 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Stokes Capital Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.